We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Two senators are pressing the Department of Health and Human Services to authorize prescription drug importation to combat price manipulation. Read More
To spur greater mutual inspection reliance between the FDA and EU, the agency and Congress are working to grant the EMA access to unredacted inspection reports. Read More
Pfizer and Allergan announced Nov. 23 that they have struck an agreement on their rumored merger, joining forces in a massive $160 billion deal that would create the world’s largest drugmaker and combine brand names such as Botox, Lipitor and Viagra. Read More
Despite a vast, “herculean feat” to obtain clinical trial data, the effect of Merck’s lipid-lowering Vytorin on cardiovascular health was just too small — with worrying holes in data that could hinder any proof of clinical meaningfulness, FDA advisors said. Read More
Following congressional outcry, an NIH task force issued findings that show underlying problems with its now-shuttered drug compounding facilities were “widespread and longstanding,” but did not cause any direct harm to patients. Read More
Are pharma companies getting what they pay for in terms of R&D spending? According to a new report from the Deloitte Center for Health Solutions, the answer is no. Read More